#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rett syndrome Amyotrophic lateral sclerosis gene carrier Exudative retinopathy Cardiac sarcoidosis Myeloid leukaemia Primary amyloidosis Hidradenitis Fusarium infection Encephalitis autoimmune Thromboangiitis obliterans Oesophageal squamous cell carcinoma stage II Dupuytren's contracture Transitional cell carcinoma Peritoneal neoplasm Osteochondrodysplasia More trials…

    Learn about Rare Diseases

    Primary hyperoxaluria – Trials in Disease Pituitary-dependent Cushing’s syndrome – Basic Information Leukoencephalopathy Ornithine transcarbamoylase deficiency – Trials in Disease Congenital generalised lipodystrophy – Diagnostics Mucopolysaccharidosis – Basic Information Primary mediastinal large B-cell lymphoma – Diagnostics Pelizaeus-Merzbacher disease – Basic Information Brain stem glioma – Life with Disease Hairy cell leukaemia recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Phenol, Liquefied Nemolizumab Izorlisib Mesilate Azd9550 Tobevibart Miglustat Dapansutrile Diclofenac Epolamine Timrepigene Emparvovec Sirolimus Lovastatin Sodium Chloride Bosentan Panitumumab Choriogonadotropin Alfa Lixisenatide Milvexian COBALAMIN Azenosertib A/H1N1 INFLUENZA VACCINE More therapies…

    Learn about Your Condition

    EGFR gene mutation Liver transplant White matter lesion Colitis Lichen planus Hyponatraemia Sickle cell disease Indolent systemic mastocytosis Cholangiosarcoma Biliary tract operation Gestational diabetes Type 2 diabetes mellitus Meniscus operation Stomatitis Candida infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study on the Safety and Effectiveness of Hydroxypropylbetadex and Miglustat for Patients with Niemann-Pick Disease Type C1

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Niemann-Pick disease
    Investigated Drugs:
    • Hydroxypropylbetadex
    • Miglustat
    Germany Italy Poland Spain
  • Study on the Effects of Maridebart Cafraglutide for Adults with Type 2 Diabetes

    Not recruiting

    2 1
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Greece Hungary Italy Poland Romania +2
  • Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Bimekizumab
    • Risankizumab
    Bulgaria Czechia Germany Hungary Poland Spain
  • Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma stage II
    • Mantle cell lymphoma stage III
    • Mantle cell lymphoma stage IV
    Investigated Drugs:
    • Ibrutinib
    Belgium Czechia Denmark Finland Germany Italy +6
  • Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary amyloidosis
    Investigated Drugs:
    • Birtamimab
    • Bortezomib
    • Sodium Chloride
    Austria Belgium Czechia Denmark France Germany +8
  • Study on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Durvalumab
    Bulgaria France Hungary Italy The Netherlands Poland +2
Previous Page
1 … 1,622 1,623 1,624 1,625 1,626 1,627
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!